-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Benzinga·07/01/2026 13:29:24
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ:HELP) with a Buy and lowers the price target from $45 to $42.